Published jointly by six leading medical societies, a new expert consensus calls for the next evolution of ALARA and recognizes Enhanced Radiation Protection Devices (ERPDs) as a critical component of modern radiation safety. Rampart’s Lead-Free ERPD™ platform is helping hospitals implement these recommendations today through clinically validated, lead-free protection.

Healthcare teams in more than 35 states are now performing lead-apron-free procedures with Rampart’s Lead-Free ERPD™. Learn how Arizona’s new legislation marks another milestone in the growing movement toward safer, lead-free radiation protection.

Rampart is able to consistently deliver next-generation radiation protection to your lab within 30 days.

Mr. Williamson has over 25 years of medical device leadership experience, including helping scale Shockwave Medical to $500M+ in annual revenue.

Mr. Burbach brings decades of medical device leadership as the company advances its interventional radiation safety platform.

A coordinated series of clinical studies spanning multiple interventional specialties all evaluating the use of Rampart’s suite of Enhanced Radiation Protection Devices (ERPD).

Presentation Features First EVAR Case Performed with the Rampart Guardian—Achieving Radiation Exposure Lower Than a Cross-Country Flight

The Next Generation of Interventional Team Protection

The Next Generation of Interventional Team Protection

Rampart IC, a Birmingham-based medical technology company, announced the successful close of its $21.6 million Series B funding round led by Vensana Capital.